6/3/2010, Thursday
FOR RELEASE 6/3/2010, Thursday
First Innovation in Ocular Anti-Viral Therapy inU.S.in Three Decades
ROCHESTER, N.Y. -- Bausch + Lomb, the global eye health company, has acquired the assets and U.S. rights for Zirgan® (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics, Inc. In 2007, Sirion Therapeutics acquired a license for the Zirgan product technology and trademark from Laboratoires Théa, headquartered in France, for the U.S. market.
###
About Bausch + Lomb
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.